Key facts
- This page summarizes Michael Torok's Form 4 filing for Carisma Therapeutics Inc. (CARM).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2023, 20:25.
Michael Torok - 07 Mar 2023 Form 4 Insider Report for Carisma Therapeutics Inc. (CARM)
- Reporting relationship
- Director
- Issuer ticker
- CARM
- Reported as of
- 07 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2023, 20:25:03 UTC
- Next SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Morris, as Attorney-in-Fact for Michael Torok
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Torok filed Form 4 for Carisma Therapeutics Inc. (CARM) on 09 Mar 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARM
transaction
Common Stock
Award
- Transaction value
- Shares
- +51,250
- Change %
- Price
- Shares after
- 51,250
- Date
- 07 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CARM
transaction
Common Stock
Award
- Transaction value
- Shares
- +319,991
- Change %
- Price
- Shares after
- 319,991
- Date
- 07 Mar 2023
- Ownership
- see footenote
- Footnotes
- F1, F2, F3
CARM
transaction
Common Stock
Award
- Transaction value
- Shares
- +50,000
- Change %
- Price
- Shares after
- 50,000
- Date
- 07 Mar 2023
- Ownership
- see footenote
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions.
Footnote F2
The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc."
Footnote F3
These shares are held of record by JEC II Associates, LLC. The Reporting Person is the Manager of JEC II Associates, LLC and has sole voting and dispositive power over the shares. The Reporting Person disclaims beneficial ownership of all shares held by JEC II Associates, LLC except to the extent of his pecuniary interest therein, if any.
Footnote F4
These securities are held of record by the K. Peter Heiland 2008 Irrevocable Trust. The Reporting Person is the Trustee of the K. Peter Heiland 2008 Irrevocable Trust and has sole voting and dispositive power over the shares. The Reporting Person disclaims beneficial ownership of all shares held by the K. Peter Heiland 2008 Irrevocable Trust except to the extent of his pecuniary interest therein, if any.